Not Yet RecruitingPhase 2

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

United States100 participantsStarted 2026-06-28

Plain-language summary

This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 18-75 years of age.
✓. Diagnosis of cHL or DLBCL that is either:
✓. Tumor biopsy positive for CD70 \>/= 10% by immunohistochemistry or flow cytometry.
✓. Measurable disease, defined by one or more histologically confirmed hypermetabolic lesion on PET/CT scan.
✓. ECOG PS ≤ 2 (Karnofsky ≥60%).
✓. Adequate blood counts (WBC \> 2K, HGB \> 8 g/dL, platelets \> 50K).
✓. Creatinine clearance ≥ 30 ml/min.
✓. ALT and/or AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.

✕8. Ability to understand and the willingness to sign a written informed consent document.
✕9. Agree to sign consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies.
✕. Lymphoma in CR with no measurable sites of disease.
✕. Major surgery \<4 weeks prior to first dose of study drug.
✕. Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.

Safety and Adverse Events (AEs)

Timeframe: Through study completion; an average of 1 year

NCT IDNCT07164469

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-09-30

Yago Nieto, MD,PHD